Intact Vascular to Sponsor Post-Angioplasty Dissection Symposium at 2019 New Cardiovascular Horizons Conference

Presentations Highlight the Tack Endovascular System^®
for Focal Dissection Repair Device Following Balloon Angioplasty

WAYNE, Pa.–(BUSINESS WIRE)–Intact
Vascular, Inc., a developer of medical devices for minimally
invasive peripheral vascular procedures, today announced the schedule of
key presentations to be featured during a lunch symposium at the 2019
New Cardiovascular Horizons (NCVH) Conference, May 29^th
through 31^st at The Roosevelt New Orleans in New Orleans,
Louisiana.

Recently FDA-approved for above-the-knee interventions, the Tack
Endovascular System is a first-of-its-kind dissection repair device
implanted post-angioplasty to resolve dissections in patients with
peripheral arterial disease (PAD). Balloon angioplasty, whether
performed with plain or drug-coated balloons, inherently injures the
vessel wall, creating dissections that may inhibit blood flow and
promote thrombosis formation. Despite the prevalence of dissections,
they are frequently underdiagnosed and left untreated, often leading to
further complications and compromised patient outcomes.

“Post-angioplasty dissections can have a significant clinical impact as
demonstrated by high rates of restenosis and re-intervention,” said
Bruce Shook, President and CEO of Intact Vascular. “We are pleased to
have such a robust program this year at the NCVH Conference, showcasing
the importance of treating dissections with the Tack Endovascular
System, a minimal metal solution that improves angioplasty outcomes and
preserves future treatment options for patients.”

The lunch symposium, “Precision Dissection Repair with the Tack
Endovascular System: Evidence and Early Experience”, will be held
from 12:00 to 12:55PM on Wednesday, May 29^th in the Blue
Room, Lobby Level. The symposium will feature presentations by Dr.
George Adams, Dr. Ehrin Armstrong, Dr. Mohammad (Mac) Ansari and Dr.
Nicolas Shammas.

Additionally, Dr. Ehrin Armstrong will present, “Tack Endovascular
Device: TOBA II Trial” on Thursday, May 30^th at 2:44PM in
the Crescent City Ballroom, Mezzanine Level.

Visit Intact Vascular at booth #206 or attend one of the presentations
to learn more about the Tack Endovascular System.

About Intact Vascular and the Tack Endovascular System

Intact Vascular is a privately held medical device company that develops
minimally- invasive peripheral vascular products. The Tack Endovascular
System is designed to repair dissections following peripheral balloon
angioplasty. Pre-loaded with six self-expanding nitinol implants for
above-the-knee (ATK) interventions, the Tack Endovascular System can be
deployed to treat multiple dissections using a single catheter and
leaving behind >70% less metal than stents.¹ Additionally,
the Tack Endovascular System is designed to minimize vessel
inflammation, promote healing, improve outcomes and preserve future
treatment options for peripheral arterial disease patients. Visit www.intactvascular.com
for more information.

Intact Vascular Clinical Program

Intact Vascular is sponsoring three clinical trials to evaluate its Tack
Endovascular System: TOBA II, TOBA II BTK and TOBA III. TOBA II is
investigating the combination of the Tack^® implant with plain
angioplasty balloons and the BD Interventional Lutonix^®
drug-coated balloon (DCB) in arteries above the knee and has completed
its primary endpoint analysis. TOBA II BTK has completed enrollment and
is investigating the combination of the Tack implant with plain balloon
angioplasty in the arteries below the knee. TOBA III has completed
enrollment in Europe and is investigating the combination of the Tack
implant with the Medtronic IN.PACT^® Admiral^®
(DCB), with a long lesion subset.

This press release contains “forward-looking statements” concerning the
development of Intact Vascular’s products, the benefits and attributes
of such products, and the company’s expectations regarding its
prospects. Forward-looking statements are subject to risks, assumptions
and uncertainties that could cause actual future events or results to
differ materially from such statements. These statements are made as of
the date of this press release. Actual results may vary. Intact Vascular
undertakes no obligation to update any forward-looking statements for
any reason.

¹Bosiers M, Scheinert D, Hendricks JMH et al. Results from
the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the
benefits of minimal metal implants for dissection repair after
angioplasty. J Vasc Surg 2016;64:109-16.

Tack Endovascular System^® and Tack^® are registered
trademarks of Intact Vascular, Inc.
Lutonix^® is a
registered trademark of BD Interventional.
IN.PACT^® and
Admiral^® are registered trademarks of Medtronic, Inc.
The
Tack Endovascular System^® is CE Mark Authorized under EC
Directive 93/42/EEC.

Contacts

Intact Vascular, Inc.
Andrea Dunkle, 1-484-253-1048